Prolonged stable disease in a uveal melanoma patient with germline MBD4 nonsense mutation treated with pembrolizumab and ipilimumab
There is currently no effective treatment for metastasised uveal melanoma (UM). Recently, it was reported that a UM patient was responsive to checkpoint inhibitor (CI) treatment, due to a high tumour mutation burden correlated with a germline loss-of-function MBD4 mutation. Here, we report on another UM patient who carried an MBD4 germline nonsense variant (p.Leu563Ter) and her tumour showed a fivefold higher than average mutation burden. We confirmed the association between germline loss-of-function variant in MBD4 and CI response. The patient experienced stable disease (10 months) and survived 2 years with metastatic disease, which is twice as long as median survival. Additionally, the frequency of MBD4 loss-of-function variants in reported UM cohorts was > 20 times higher than in an aggregated population genome database (P < 5 × 10−5), implying a potential role as UM predisposition gene. These findings provide a strong basis for the inclusion of MBD4 in the screening of potential UM-prone families as well as stratification of immunotherapy.
KeywordsMBD4 Uveal melanoma Mutation Immunotherapy Predisposition gene
We are indebted to the patient and her family and acknowledge the contribution of Dr. Grant Cameron, along with the many clinicians and allied health professionals involved in her care. We are grateful to Dr. Robert Rawson, Dr. Michael Walsh, Dr. Ken Dutton-Regester, Dr. Lauren Aoude, Madeleine Howlie and Hayley Hamilton for input into this study.
The work was funded by the National Health and Medical Research Council of Australia (NHMRC 1093017). N.K.H. is supported by a fellowship from the NHMRC (1117663).
Compliance with ethical standards
Ethics approval was obtained from the Human Research Ethics Committees of the QIMR Berghofer Medical Research Institute. Written informed consent was obtained from the patient.
- Furney SJ, Pedersen M, Gentien D, Dumont AG, Rapinat A, Desjardins L, Turajlic S, Piperno-Neumann S, de la Grange P, Roman-Roman S, Stern MH, Marais R (2013) SF3B1 mutations are associated with alternative splicing in uveal melanoma. Cancer Discov 3:1122–1129. https://doi.org/10.1158/2159-8290.CD-13-0330 CrossRefGoogle Scholar
- Johansson P, Aoude LG, Wadt K, Glasson WJ, Warrier SK, Hewitt AW, Kiilgaard JF, Heegaard S, Isaacs T, Franchina M, Ingvar C, Vermeulen T, Whitehead KJ, Schmidt CW, Palmer JM, Symmons J, Gerdes AM, Jönsson G, Hayward NK (2016) Deep sequencing of uveal melanoma identifies a recurrent mutation in PLCB4. Oncotarget 7:4624–4631. https://doi.org/10.18632/oncotarget.6614 Google Scholar
- Martin M, Maßhöfer L, Temming P, Rahmann S, Metz C, Bornfeld N, van de Nes J, Klein-Hitpass L, Hinnebusch AG, Horsthemke B, Lohmann DR, Zeschnigk M (2013) Exome sequencing identifies recurrent somatic mutations in EIF1AX and SF3B1 in uveal melanoma with disomy 3. Nat Genet 45:933–936. https://doi.org/10.1038/ng.2674 CrossRefGoogle Scholar
- Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, Lee W, Yuan J, Wong P, Ho TS, Miller ML, Rekhtman N, Moreira AL, Ibrahim F, Bruggeman C, Gasmi B, Zappasodi R, Maeda Y, Sander C, Garon EB, Merghoub T, Wolchok JD, Schumacher TN, Chan TA (2015) Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348:124–128. https://doi.org/10.1126/science.aaa1348 CrossRefGoogle Scholar
- Robertson AG, Shih J, Yau C, Gibb EA, Oba J, Mungall KL, Hess JM, Uzunangelov V, Walter V, Danilova L, Lichtenberg TM, Kucherlapati M, Kimes PK, Tang M, Penson A, Babur O, Akbani R, Bristow CA, Hoadley KA, Iype L, Chang MT, Cherniack AD, Benz C, Mills GB, Verhaak RGW, Griewank KG, Felau I, Zenklusen JC, Gershenwald JE, Schoenfield L, Lazar AJ, Abdel-Rahman MH, Roman-Roman S, Stern MH, Cebulla CM, Williams MD, Jager MJ, Coupland SE, Esmaeli B, Kandoth C, Woodman SE, Abdel-Rahman MH, Akbani R, Ally A, Auman JT, Babur O, Balasundaram M, Balu S, Benz C, Beroukhim R, Birol I, Bodenheimer T, Bowen J, Bowlby R, Bristow CA, Brooks D, Carlsen R, Cebulla CM, Chang MT, Cherniack AD, Chin L, Cho J, Chuah E, Chudamani S, Cibulskis C, Cibulskis K, Cope L, Coupland SE, Danilova L, Defreitas T, Demchok JA, Desjardins L, Dhalla N, Esmaeli B, Felau I, Ferguson ML, Frazer S, Gabriel SB, Gastier-Foster JM, Gehlenborg N, Gerken M, Gershenwald JE, Getz G, Gibb EA, Griewank KG, Grimm EA, Hayes DN, Hegde AM, Heiman DI, Helsel C, Hess JM, Hoadley KA, Hobensack S, Holt RA, Hoyle AP, Hu X, Hutter CM, Jager MJ, Jefferys SR, Jones CD, Jones SJM, Kandoth C, Kasaian K, Kim J, Kimes PK, Kucherlapati M, Kucherlapati R, Lander E, Lawrence MS, Lazar AJ, Lee S, Leraas KM, Lichtenberg TM, Lin P, Liu J, Liu W, Lolla L, Lu Y, Iype L, Ma Y, Mahadeshwar HS, Mariani O, Marra MA, Mayo M, Meier S, Meng S, Meyerson M, Mieczkowski PA, Mills GB, Moore RA, Mose LE, Mungall AJ, Mungall KL, Murray BA, Naresh R, Noble MS, Oba J, Pantazi A, Parfenov M, Park PJ, Parker JS, Penson A, Perou CM, Pihl T, Pilarski R, Protopopov A, Radenbaugh A, Rai K, Ramirez NC, Ren X, Reynolds SM, Roach J, Robertson AG, Roman-Roman S, Roszik J, Sadeghi S, Saksena G, Sastre X, Schadendorf D, Schein JE, Schoenfield L, Schumacher SE, Seidman J, Seth S, Sethi G, Sheth M, Shi Y, Shields C, Shih J, Shmulevich I, Simons JV, Singh AD, Sipahimalani P, Skelly T, Sofia H, Soloway MG, Song X, Stern MH, Stuart J, Sun Q, Sun H, Tam A, Tan D, Tang M, Tang J, Tarnuzzer R, Taylor BS, Thiessen N, Thorsson V, Tse K, Uzunangelov V, Veluvolu U, Verhaak RGW, Voet D, Walter V, Wan Y, Wang Z, Weinstein JN, Wilkerson MD, Williams MD, Wise L, Woodman SE, Wong T, Wu Y, Yang L, Yang L, Yau C, Zenklusen JC, Zhang J, Zhang H, Zmuda E (2017) Integrative analysis identifies four molecular and clinical subsets in uveal melanoma. Cancer Cell 32:204–220 e215. https://doi.org/10.1016/j.ccell.2017.07.003 CrossRefGoogle Scholar
- Rodrigues M, Mobuchon L, Houy A, Fiévet A, Gardrat S, Barnhill RL, Popova T, Servois V, Rampanou A, Mouton A, Dayot S, Raynal V, Galut M, Putterman M, Tick S, Cassoux N, Roman-Roman S, Bidard FC, Lantz O, Mariani P, Piperno-Neumann S, Stern MH (2018) Outlier response to anti-PD1 in uveal melanoma reveals germline MBD4 mutations in hypermutated tumors. Nat Commun 9:1866. https://doi.org/10.1038/s41467-018-04322-5 CrossRefGoogle Scholar
- Sanders MA et al (2018) MBD4 guards against methylation damage and germline deficiency predisposes to clonal hematopoiesis and early-onset AML. Blood. https://doi.org/10.1182/blood-2018-05-852566
- Waszak SM et al (2017) Germline determinants of the somatic mutation landscape in 2,642 cancer genomes. bioRxiv. https://doi.org/10.1101/208330